Cartherics Pty Ltd.

Plus, news about IN8bio, Sanofi, Vicore Pharma, Cartherics, Zephyrm Bioscience, Tharimmune and Intract Pharma: Biohaven’s $250M offering: The move comes after Biohaven announced Monday that it started a pivotal Phase 2 study of its oral TRPM3 antagonist for migraines. The company also expects to grant the underwriters another $37.5 million of common shares. — Katherine Lewin Activist firm grows stake in Galapagos: EcoR1 crossed the 10% ownership threshold tied to voting securities, according to a disclosure on Monday . EcoR1 believes the Dutch biotech is “deeply undervalued” and previously said it would speak to the board and management about a “variety of topics” including board composition. — Max Bayer IN8bio’s $12.4M raise: The New York gamma-delta T cell therapy biotech priced the private placement a few weeks after announcing plans to prioritize its pipeline and halve its workforce. — Kyle LaHucik Sanofi invests $10M in Vicore Pharma: The Stockholm-based company is beginning a Phase 2b trial investigating its drug, buloxibutid, in patients with idiopathic pulmonary fibrosis who are either untreated or receiving the current standard of care. — Katherine Lewin Cartherics raises about $10 million: The money is set to go toward a clinical trial next year for the Melbourne-based company’s preclinical lead cell therapy for ovarian cancer, dubbed CTH-401. According to Cartherics, CTH-401 is the only natural killer cell therapy currently under development that includes a CAR that targets the adenocarcinoma specific antigen called TAG-72. — Katherine Lewin Zephyrm Bioscience files for IPO in Hong Kong: The seven-year-old startup wants to go public on the Hong Kong Stock Exchange to fund its pipeline of pluripotent stem cell therapies. Its lead therapy is expected to enter Phase 3 next year for two indications: acute exacerbation of interstitial lung disease, and acute graft versus host disease. — Kyle LaHucik Tharimmune, Intract Pharma to merge: The clinical-stage I&I biotech wants to combine with Intract, which makes a delivery system for oral biologics. The merger is slated to close in the first quarter of 2025, and Intract shareholders will own 49% of the combined company. — Kyle LaHucik

Melbourne, Australia, 12 June 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its first Australian patent, AU2016361451, entitled “Genetically modified cells and uses thereof”, providing patent support for multiple development candidates in the Company’s pipeline. This patent enhances Cartherics’ expanding intellectual property portfolio and covers aspects of the Company’s chimeric antigen receptor (CAR) technology, particularly in relation to its CAR directed against the tumour-associated antigen, TAG-72. TAG-72 is highly expressed on a range of adenocarcinomas, including ovarian and gastric cancers. The patent issuance marks a significant milestone in developing innovative, new treatments for these cancers. The Australian patent is part of a broader patent family, with applications for similar protection filed in key jurisdictions such as the US, Japan, and Europe. In addition, Cartherics has also filed a divisional application covering other aspects of this invention. This granted patent provides Cartherics protection for its TAG-72 CAR construct. T cells or natural killer (NK) cells carrying the CAR have demonstrated as compelling efficacy against human ovarian cell lines, in both in vitro and in vivo. The Company’s lead product CTH-401, incorporates the TAG-72 CAR and the initial indication for this product is relapsed or refractory ovarian cancer, where over 90 percent of tumours are TAG-72 positive. Ovarian cancer is the leading cause of death in women diagnosed with gynaecological cancers and also the fifth most leading cause of death in women, in general. Targeting these tumours with novel cellular immunotherapies will help address the unmet need for new treatment options for these patients. The global ovarian cancer treatment drugs market size was valued at US$2.50 billion in 2023 and the worldwide ovarian cancer treatment drugs market size is expected to reach US$5.45 billion by 2033.[i] Cartherics’ CEO, Prof. Alan Trounson AO, commented: “The award of this patent strengthens our global position in cancer therapy and potentially other intractable disease conditions. This creates a very good position for the Company”. ****** About Cartherics  Cartherics is a privately held biotechnology company based in Melbourne, Australia that is rearming the body’s immune system to fight cancer.  It is developing cell-based immunotherapies for the treatment of cancer, with a portfolio of CAR-T and CAR-NK cell products.  The Company’s allogeneic (“off-the-shelf”) cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system.  The iPSCs are genetically engineered at specific “safe harbour” genomic sites to provide enhanced function for the derived NK and other immune cells. The Company’s lead product, CTH-401, is a CAR-NK cell product. It carries a CAR directed against TAG-72, a well-validated tumour target, along with the deletion of two genes associated with immunosuppression.  Media contact Christine Filippis  Teraze Communications Phone: +61 419 119 866  Email: christine@teraze.com.au [i]

Melbourne, Australia, 23 May 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family represented by the international patent filing WO2017088012. The European Patent No. 3708587 B1, titled 'Genetically Modified Cells and Uses Thereof,' secures a proprietary position for multiple development candidates in the Company’s pipeline. Specifically, this patent covers stem cells bearing the Cartherics’ chimeric antigen receptor (CAR) targeting the tumour-associated glycoprotein-72 (TAG-72). It also provides protection for allogeneic (off-the-shelf) immune cell products derived from the stem cells carrying the TAG-72 CAR. TAG-72 is highly expressed on a range of adenocarcinomas, including ovarian and gastric cancers. Issuance of the patent is an important milestone in the development of new treatments for these cancers and adds to Cartherics’ substantial intellectual property portfolio. Cartherics’ initial target indication is relapsed or refractory ovarian cancer, where greater than 90 percent of tumours are TAG-72 positive. Targeting these tumours with novel cellular immunotherapies will help address the unmet need for new treatment options for these patients. Cartherics’ CEO, Prof. Alan Trounson AO, commented: “Cartherics has invested heavily to secure patent protection for different aspects of its technology platform. The issuance of this European patent adds to the web of patents underpinning development and commercialisation of the Company’s products, in particular its lead product, CTH-401.” ****** About Cartherics  Cartherics is a privately held biotechnology company based in Melbourne, Australia that is rearming the body’s immune system to fight cancer.  It is developing cell-based immunotherapies for the treatment of cancer, with a portfolio of CAR-T and CAR-NK cell products.  The Company’s allogeneic (“off-the-shelf”) cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system.  The iPSCs are genetically engineered at specific “safe harbour” genomic sites to provide enhanced function for the derived NK and other immune cells. The Company’s lead product, CTH-401, is a CAR-NK cell product. It carries a CAR directed against TAG-72, a well-validated tumour target, along with the deletion of two genes associated with immunosuppression.  Media contact Christine Filippis  Teraze Communications Phone: +61 419 119 866  Email: christine@teraze.com.au